WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Tuesday, August 15, 2006

Hide?	Set Name	Query	Hit Count
		DB=PGPB,USPT,EPAB; PLUR=YES; OP=ADJ	
☐	L46	L45 not @py>2001	3
☐	L45	L29 and L7	33
☐	L44	L29 and L27	0
☐	L43	5955432.pn.	1
☐	L42	5767086.pn.	1
☐	L41	L40 not @py>2001	52
☐	L40	L39 not @ay>2001	97
☐	L39	L38 and L7	219
☐	L38	glutathione SAME prodrug	252
☐	L37	TER and glutathione	1042
☐	L36	L35 and glutathione	19
☐	L35	L34 not @ay>2001	31
☐	L34	L33 and carboplatin	98
☐	L33	L32 and L7	573
☐	L32	TER and prodrug	787
☐	L31	L30 not @ay>2001	3
☐	L30	L29 and carboplatin	24
☐	L29	TER286 or (TER-286) or (TER 286)	33
☐	L28	5880097.pn.	1
☐	L27	L4 and L7	1
☐	L26	L7 and L11	1
☐	L25	L24 and L3	8
☐	L24	L23 and L7	132
☐	L23	L22 and L14	157
☐	L22	L21 or L20	3792
☐	L21	(530/331 |530/345)![CCLS]	2582
☐	L20	(514/18)![CCLS]	2139
☐	L19	L18 and L16	55
☐	L18	L7.ab.	41561
☐	L17	L16 and L7	133
☐	L16	L15.ab.	264

☐	L15	GST or (glutathione NEAR3 transferase)	25854
☐	L14	GST or (glutathione NEAR2 transferase)	25839
☐	L13	L12 and L7	58
☐	L12	(ter NEAR2 286) or (TLK NEAR2 286)	58
☐	L11	("5556942").PN.	1
☐	L10	L9 not @py>2001	17
☐	L9	L8 and L6	150
☐	L8	L7.clm.	39760
☐	L7	cancer$ or neoplas$ or tumor$	196960
☐	L6	L5.clm.	284
☐	L5	combination therapy	16894
☐	L4	5908919.pn.	1
☐	L3	L2 or L1	58
☐	L2	tlk 286	31
☐	L1	ter 286	28

END OF SEARCH HISTORY

$%^STN;HighlightOn= ***;HighlightOff=*** ;

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 01 New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS 4 OCT 28 KOREAPAT now available on STN
NEWS 5 NOV 30 PHAR reloaded with additional data
NEWS 6 DEC 01 LISA now available on STN
NEWS 7 DEC 09 12 databases to be removed from STN on December 31, 2004
NEWS 8 DEC 15 MEDLINE update schedule for December 2004
NEWS 9 DEC 17 ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS 10 DEC 17 COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS 11 DEC 17 SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS 12 DEC 17 CERAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS 13 DEC 17 THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS 14 DEC 30 EPFULL: New patent full text database to be available on STN
NEWS 15 DEC 30 CAPLUS - PATENT COVERAGE EXPANDED
NEWS 16 JAN 03 No connect-hour charges in EPFULL during January and February 2005
NEWS 17 FEB 25 CA/CAPLUS - Russian Agency for Patents and Trademarks (ROSPATENT) added to list of core patent offices covered
NEWS 18 FEB 10 STN Patent Forums to be held in March 2005
NEWS 19 FEB 16 STN User Update to be held in conjunction with the 229th ACS National Meeting on March 13, 2005
NEWS 20 FEB 28 PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS 21 FEB 28 BABS - Current-awareness alerts (SDIs) available
NEWS 22 FEB 28 MEDLINE/LMEDLINE reloaded
NEWS 23 MAR 02 GBFULL: New full-text patent database on STN
NEWS 24 MAR 03 REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS 25 MAR 03 MEDLINE file segment of TOXCENTER reloaded
NEWS 26 MAR 22 KOREAPAT now updated monthly; patent information enhanced
NEWS 27 MAR 22 Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS 28 MAR 22 PATDPASPC - New patent database available
NEWS 29 MAR 22 REGISTRY/ZREGISTRY enhanced with experimental property ta

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRI
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

```
 * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:35:18 ON 25 MAR 2005

=> file reg
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                              ENTRY    SESSION
FULL ESTIMATED COST                            0.21       0.21

FILE 'REGISTRY' ENTERED AT 10:35:27 ON 25 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:  24 MAR 2005  HIGHEST RN 847222-24-6
DICTIONARY FILE UPDATES:  24 MAR 2005  HIGHEST RN 847222-24-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*************************************************************************
*                                                                       *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                       *
*************************************************************************

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> E "CANGLUSTRATIDE"/CN 25
E1          1    CANFOSFAMIDE/CN
E2          1    CANGITOXIN (REDUCED)/CN
E3          0 --> CANGLUSTRATIDE/CN
E4          1    CANGLUSTRATIDE HYDROCHLORIDE/CN
E5          1    CANGORIN A/CN
E6          1    CANGORIN B/CN
E7          1    CANGORIN C/CN
E8          1    CANGORIN D/CN
E9          1    CANGORIN E/CN
E10         1    CANGORIN F/CN
E11         1    CANGORIN G/CN
E12         1    CANGORIN H/CN
E13         1    CANGORIN I/CN
E14         1    CANGORIN J/CN
E15         1    CANGORINE A/CN
E16         1    CANGORINE B/CN
E17         1    CANGORINE C/CN
E18         1    CANGORINE D/CN
E19         1    CANGORINE E/CN
E20         1    CANGORINE F/CN
E21         1    CANGORINE G/CN
E22         1    CANGORINE G 10-ACETATE/CN
E23         1    CANGORINE H/CN
E24         1    CANGORINE I/CN
E25         1    CANGORINE J/CN

=> S E4
L1          1 "CANGLUSTRATIDE HYDROCHLORIDE"/CN

=> DIS L1 1 SQIDE
THE ESTIMATED COST FOR THIS REQUEST IS 6.15 U.S. DOLLARS
```

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN 439943-59-6 REGISTRY
CN Glycine, L-.gamma.-glutamyl-3-[[2-[[bis[bis(2-chloroethyl)amino]phosphinyl]oxy]ethyl]sulfonyl]-L-alanyl-2-phenyl-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN ***Canglustratide hydrochloride***
CN TER 286
CN TLK 286
FS STEREOSEARCH
MF C26 H40 Cl4 N5 O10 P S . Cl H
SR CAS Client Services
LC STN Files: ADISINSIGHT, CA, CAPLUS, PHAR, PROUSDDR, SYNTHLINE, TOXCENTER, USPATFULL
DT.CA CAplus document type: Conference; Journal; Patent
RL.P Roles from patents: BIOL (Biological study); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PROC (Process); USES (Uses)
CRN (158382-37-7)

Absolute stereochemistry.

/ Structure 1 in file .gra /

18 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
18 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file medline
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 6.87 7.08

FILE 'MEDLINE' ENTERED AT 10:36:18 ON 25 MAR 2005

FILE LAST UPDATED: 24 MAR 2005 (20050324/UP). FILE COVERS 1950 TO DATE

On December 19, 2004, the 2005 MeSH terms were loaded.

The MEDLINE reload for 2005 is now available. For details enter HELP RLOAD at an arrow promt (=>). See also:

http://www.nlm.nih.gov/mesh/
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2005 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l1
L2 0 L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.40 7.48

FILE 'CAPLUS' ENTERED AT 10:36:25 ON 25 MAR 2005

FILE COVERS 1907 - 25 Mar 2005 VOL 142 ISS 14
FILE LAST UPDATED: 24 Mar 2005 (20050324/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l1
L3         18 L1

=> s l3 and (cancer? or tumor? or neoplas?)
      253494 CANCER?
      384869 TUMOR?
      402446 NEOPLAS?
L4         18 L3 AND (CANCER? OR TUMOR? OR NEOPLAS?)

=> s l4 not py>2002
     2461177 PY>2002
L5          8 L4 NOT PY>2002

=> d ibib 1-4

L5  ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:       2003:61250  CAPLUS
DOCUMENT NUMBER:        139:143479
TITLE:                  Efficacy of a glutathione S-transferase .pi.-activated
                        prodrug in platinum-resistant ovarian  ***cancer***
                        cells
AUTHOR(S):              Townsend, Danyelle M.; Shen, Hongxie; Staros,
                        Alexandra L.; Gate, Laurent; Tew, Kenneth D.
CORPORATE SOURCE:       Department of Pharmacology, Fox Chase Cancer Center
                        Philadelphia, PA, 19111, USA
SOURCE:                 Molecular Cancer Therapeutics (2002), 1(12), 1089-1095
                        CODEN: MCTOCF; ISSN: 1535-7163
PUBLISHER:              American Association for Cancer Research
DOCUMENT TYPE:          Journal
LANGUAGE:               English
REFERENCE COUNT:        24    THERE ARE 24 CITED REFERENCES AVAILABLE
                        RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5  ANSWER 2 OF 8  CAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:       2001:316848  CAPLUS
DOCUMENT NUMBER:        135:116763
TITLE:                  The influence of GST-targeted drugs on cell
                        proliferation and stress response
AUTHOR(S):              Tew, Kenneth D.
CORPORATE SOURCE:       Department of Pharmacology, Fox Chase Cancer Center
                        Philadelphia, PA, USA
SOURCE:                 Chemico-Biological Interactions (2001), 133(1-3),
                        295-300
                        CODEN: CBINA8; ISSN: 0009-2797
PUBLISHER:              Elsevier Science Ireland Ltd.
DOCUMENT TYPE:          Journal
LANGUAGE:               English
REFERENCE COUNT:        5     THERE ARE 5 CITED REFERENCES AVAILABLE FO
                        RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5  ANSWER 3 OF 8  CAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:       2000:466901  CAPLUS
DOCUMENT NUMBER:        133:171845
TITLE:                  Cellular response to a glutathione S-transferase P1-1
                        activated prodrug
AUTHOR(S):              Rosario, Lilliam A.; O'Brien, Miechelle L.; Henderson,
                        Colin J.; Wolf, C. Roland; Tew, Kenneth D.
```

CORPORATE SOURCE: Department of Pharmacology, Fox Chase Cancer Center Philadelphia, PA, USA
SOURCE: Molecular Pharmacology (2000), 58(1), 167-174
CODEN: MOPMA3; ISSN: 0026-895X
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:402062 CAPLUS
DOCUMENT NUMBER: 129:117526
TITLE: ***Tumor*** efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase
AUTHOR(S): Morgan, Amy S.; Sanderson, Polly E.; Borch, Richard F.; Tew, Kenneth D.; Niitsu, Yoshiro; Takayama, Tetsuji; Von Hoff, Daniel D.; Izbicka, Elzbieta; Mangold, Gina; Paul, Christer; Broberg, Ulrika; Mannervik, Bengt; Henner, W. David; Kauvar, Lawrence M.
CORPORATE SOURCE: Terrapin Technologies, Inc., South San Francisco, CA, 94080, USA
SOURCE: Cancer Research (1998), 58(12), 2568-2575
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 5-8

L5 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1997:348755 CAPLUS
DN 127:60274
TI Activity of TER286 against human ***tumor*** colony-forming units
AU Izbicka, Elzbieta; Lawrence, Richard; Cerna, Caesar; Von Hoff, Daniel D.; Sanderson, Polly E.
CS Inst. Drug Development, Cancer Therapy Res. Center, San Antonio, TX, 78245, USA
SO Anti-Cancer Drugs (1997), 8(4), 345-348
CODEN: ANTDEV; ISSN: 0959-4973
PB Rapid Science Publishers
DT Journal
LA English
RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECOR ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1996:695835 CAPLUS
DN 126:554
TI Glutathione-based anti- ***cancer*** drugs: Animal efficacy and bone marrow sparing effects
AU Lyttle, M. H.; Satyam, A.; Hocker, M. D.; Hui, H. C.; Caldwell, C. G.; Morgan, A. S.; Stanboli, A.; Kauvar, L. M.
CS Terrapin Technologies, South San Francisco, CA, 94080, USA
SO Peptides: Chemistry, Structure and Biology, Proceedings of the American Peptide Symposium, 14th, Columbus, Ohio, June 18-23, 1995 (1996), Meeting Date 1995, 170-171. Editor(s): Kaumaya, Pravin T. P.; Hodges, Robert S. Publisher: Mayflower Scientific, Kingswinford, UK.
CODEN: 63NTAF
DT Conference
LA English

L5 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1996:175896 CAPLUS
DN 124:278186
TI Design, Synthesis, and Evaluation of Latent Alkylating Agents Activated by Glutathione S-Transferase
AU Satyam, Apparao; Hocker, Michael D.; Kane-Maguire, Kim A.; Morgan, Amy S.;

Villar, Hugo O.; Lyttle, Matthew H.
CS Terrapin Technologies Inc., South San Francisco, CA, 94080, USA
SO Journal of Medicinal Chemistry (1996), 39(8), 1736-47
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English

L5 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:892014 CAPLUS
DN 124:21231
TI Modulation of detoxification gene expression in human colon HT29 cells by glutathione-S-transferase inhibitors
AU Ciaccio, Paul J.; Shen, Hongxie; Jaiswal, Anil K.; Lyttle, Matthew H.; Tew, Kenneth D.
CS Dep. Pharmacol., Fox Chase Cancer Cent., Philadelphia, PA, 19111, USA
SO Molecular Pharmacology (1995), 48(4), 639-47
CODEN: MOPMA3; ISSN: 0026-895X
PB Williams & Wilkins
DT Journal
LA English

=> file pctfull
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 17.71 25.19

FILE 'PCTFULL' ENTERED AT 10:38:07 ON 25 MAR 2005
COPYRIGHT (C) 2005 Univentio

FILE LAST UPDATED: 23 MAR 2005 <20050323/UP>
MOST RECENT UPDATE WEEK: 200511 <200511/EW>
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

=> s l1
'CN' IS NOT A VALID FIELD CODE
L6 0 "CANGLUSTRATIDE HYDROCHLORIDE"/CN

=> s canglustratide
L7 1 CANGLUSTRATIDE

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 1.05 26.24

STN INTERNATIONAL LOGOFF AT 10:38:43 ON 25 MAR 2005

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 4 APR 04 STN AnaVist $500 visualization usage credit offered
NEWS 5 MAY 10 CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 6 MAY 11 KOREAPAT updates resume
NEWS 7 MAY 19 Derwent World Patents Index to be reloaded and enhanced
NEWS 8 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS 9 MAY 30 The F-Term thesaurus is now available in CA/CAplus
NEWS 10 JUN 02 The first reclassification of IPC codes now complete in INPADOC
NEWS 11 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS 12 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 13 JUI 11 CHEMSAFE reloaded and enhanced
NEWS 14 JUI 14 FSTA enhanced with Japanese patents
NEWS 15 JUI 19 Coverage of Research Disclosure reinstated in DWPI
NEWS 16 AUG 09 INSPEC enhanced with 1898-1968 archive

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:33:34 ON 14 AUG 2006

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'CAPLUS' ENTERED AT 09:33:41 ON 14 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 14 Aug 2006 VOL 145 ISS 8
FILE LAST UPDATED: 13 Aug 2006 (20060813/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s 439943-59-6/rn
         31 439943-59-6
          2 439943-59-6D
L1        29 439943-59-6/RN
            (439943-59-6 (NOTL) 439943-59-6D )

=> s carboplatin/cn
   *** REG1stRY INITIATED ***
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.




L3       4320 L2

=> s l1 and l3
L4         11 L1 AND L3

=> d ibib 1-11

L4  ANSWER 1 OF 11  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:       2006:167588  CAPLUS <<LOGINID::20060814>>
DOCUMENT NUMBER:        144:254148
TITLE:                  Aminopteridinones as anticancer agents, their
                        preparation, pharmaceutical compositions, and use in
                        therapy
INVENTOR(S):            Munzert, Gerd; Steegmaier, Martin; Baum, Anke
PATENT ASSIGNEE(S):     Boehringer Ingelheim International G.m.b.H., Germany;
                        Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE:                 PCT Int. Appl., 158 pp.
                        CODEN: PIXXD2
DOCUMENT TYPE:          Patent
LANGUAGE:               English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

    PATENT NO.        KIND  DATE      APPLICATION NO.      DATE
    --------------    ----  --------  -------------------  --------
    WO 2006018182      A1   20060223  WO 2005-EP8623       20050809
    WO 2006018182      C1   20060608
       W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
           CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
           GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
           LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
           NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
           SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
           ZA, ZM, ZW
       RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
           IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
           CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
           GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
           KG, KZ, MD, RU, TJ, TM
    US 2006058311      A1   20060316  US 2005-189540       20050726
PRIORITY APPLN. INFO.:                 EP 2004-19361      A  20040814
                                       EP 2004-19448      A  20040817
OTHER SOURCE(S):        MARPAT 144:254148
REFERENCE COUNT:         1    THERE ARE 1 CITED REFERENCES AVAILABLE FC
                         RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4  ANSWER 2 OF 11  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:       2005:1290072  CAPLUS <<LOGINID::20060814>>
DOCUMENT NUMBER:        144:46998
TITLE:                  The X-ray crystal structure of BRCA1 tandem BRCT
                        repeat and BACH1 phosphopeptide complex and methods
                        and compositions for antitumor drug design
INVENTOR(S):            Yaffe, Michael B.; Clapperton, Julie A.; Manke, Isaac
                        A.; Lowery, Drew M.; Ho, Timmy; Haire, Lesley F.;
                        Smerdon, Stephen J.
```

PATENT ASSIGNEE(S): Massachusetts Institute of Technology, USA
SOURCE: PCT Int. Appl., 360 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005115454	A2	20051208	WO 2005-US15981	20050509

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-569131P P 20040507

L4 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1242685 CAPLUS <<LOGINID::20060814>>
DOCUMENT NUMBER: 143:472533
TITLE: GST-activated anticancer therapy for sensitization or side effect amelioration of another anticancer
INVENTOR(S): Brown, Gail L.; Keck, James G.; Wick, Michael M.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 13 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005261202	A1	20051124	US 2005-133833	20050519
WO 2005112973	A1	20051201	WO 2005-US17960	20050519

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-572790P P 20040520
OTHER SOURCE(S): MARPAT 143:472533

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1239173 CAPLUS <<LOGINID::20060814>>
DOCUMENT NUMBER: 143:477963
TITLE: Preparation of pyrazolyl urea derivatives as TrkA kinase inhibitors useful in the treatment of cancer
INVENTOR(S): Lee, Wendy; Ladouceur, Gaetan; Dumas, Jacques; Smith, Roger; Ying, Shihong; Wang, Gan; Chen, Zhi; Liu, Qingjie; Mokdad, Holia Hatoum
PATENT ASSIGNEE(S): Bayer Pharmacueticals Corporation, USA
SOURCE: PCT Int. Appl., 215 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
---------- ---- -------- ---------- --------
WO 2005110994 A2 20051124 WO 2005-US15106 20050502
WO 2005110994 A3 20060202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2004-566445P P 20040430
OTHER SOURCE(S): MARPAT 143:477963

L4 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:409543 CAPLUS <<LOGINID::20060814>>
DOCUMENT NUMBER: 142:457053
TITLE: Human protein IAP (inhibitor of apoptosis protein) nucleobase oligomers, including dsRNA, shRNA, and siRNA, and their use for enhancing apoptosis in cancer therapy
INVENTOR(S): Lacasse, Eric; McManus, Daniel
PATENT ASSIGNEE(S): Aegera Therapeutics, Inc., Can.
SOURCE: PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
---------- ---- -------- ---------- --------
WO 2005042558 A1 20050512 WO 2004-CA1902 20041029
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2005148535 A1 20050707 US 2004-975974 20041028
CA 2542904 AA 20050512 CA 2004-2542904 20041029
EP 1682565 A1 20060726 EP 2004-789809 20041029
R: DE, FR, GB
PRIORITY APPLN. INFO.: US 2003-516192P P 20031030
WO 2004-CA1902 W 20041029

L4 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:409357 CAPLUS <<LOGINID::20060814>>
DOCUMENT NUMBER: 142:457052
TITLE: Sequences of antisense IAP (inhibitor of apoptosis protein) oligomers and their use for treatment of proliferative diseases with a chemotherapeutic agent
INVENTOR(S): Lacasse, Eric; McManus, Daniel; Durkin, Jon P.
PATENT ASSIGNEE(S): Aegera Therapeutics, Inc., Can.
SOURCE: PCT Int. Appl., 285 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
---------- ---- -------- ---------- --------
WO 2005042030 A1 20050512 WO 2004-CA1900 20041029

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG
US 2005119217 A1 20050602 US 2004-975790 20041028
AU 2004284855 A1 20050512 AU 2004-284855 20041029
CA 2542884 AA 20050512 CA 2004-2542884 20041029
PRIORITY APPLN. INFO.: US 2003-516263P P 20031030
WO 2004-CA1900 W 20041029
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE F(
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:283298 CAPLUS <<LOGINID::20060814>>
DOCUMENT NUMBER: 142:349042
TITLE: Combinations of chlorpromazine compounds and
antiproliferative drugs for the treatment of neoplasms
INVENTOR(S): Lee, Margaret S.; Nichols, James M.; Zhang, Yanzhen;
Keith, Curtis
PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 2005027842 A2 20050331 WO 2004-US30368 20040916
WO 2005027842 A3 20051222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG
AU 2004273910 A1 20050331 AU 2004-273910 20040916
CA 2538570 AA 20050331 CA 2004-2538570 20040916
EP 1670477 A2 20060621 EP 2004-788798 20040916
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
PRIORITY APPLN. INFO.: US 2003-504310P P 20030918
WO 2004-US30368 W 20040916
OTHER SOURCE(S): MARPAT 142:349042

L4 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:158629 CAPLUS <<LOGINID::20060814>>
DOCUMENT NUMBER: 142:246160
TITLE: Treatment of lung cancer with vitamin D compounds in
combination with other treatments
INVENTOR(S): Henner, William D.
PATENT ASSIGNEE(S): Novacea, Inc., USA
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 2005016872 A1 20050224 WO 2004-US18427 20040610
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2004265238 A1 20050224 AU 2004-265238 20040610
CA 2528519 AA 20050224 CA 2004-2528519 20040610
EP 1631543 A1 20060308 EP 2004-776421 20040610
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK
CN 1802349 A 20060712 CN 2004-80015998 20040610
US 2006172014 A1 20060803 US 2005-298927 20051212
PRIORITY APPLN. INFO.: US 2003-477339P P 20030611
US 2004-569245P P 20040510
WO 2004-US18427 W 20040610
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FO
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:965067 CAPLUS <<LOGINID::20060814>>
DOCUMENT NUMBER: 141:406039
TITLE: Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
INVENTOR(S): Hilberg, Frank; Solca, Flavio; Stefanic, Martin Friedrich; Baum, Anke; Munzert, Gerd; Van Meel, Jacobus C. A.
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096224	A2	20041111	WO 2004-EP4363	20040424
WO 2004096224	A3	20041216		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1473043 A1 20041103 EP 2003-9587 20030429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
AU 2004233576 A1 20041111 AU 2004-233576 20040424
CA 2523868 AA 20041111 CA 2004-2523868 20040424
EP 1622619 A2 20060208 EP 2004-729366 20040424
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
BR 2004009919 A 20060425 BR 2004-9919 20040424
NO 2005005605 A 20051128 NO 2005-5605 20051128
PRIORITY APPLN. INFO.: EP 2003-9587 A 20030429
EP 2004-508 A 20040113
EP 2004-1171 A 20040121
WO 2004-EP4363 W 20040424

L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:756710 CAPLUS <<LOGINID::20060814>>
DOCUMENT NUMBER: 141:277628
TITLE: Preparation of ureidophenoxycyanopyridines as anticancer drugs.
INVENTOR(S): Scott, William J.; Dumas, Jacques; Boyer, Stephen; Lee, Wendy; Chen, Yuanwei; Phillips, Barton; Verma, Sharad; Chen, Jianqing; Chen, Zhi; Fan, Jianmei; Raudenbush, Brian; Redman, Aniko; Yi, Lin; Zhu, Qingming
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004078747	A1	20040916	WO 2004-US6286	20040301
WO 2004078747	C1	20041104		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004235829	A1	20041125	US 2004-788029	20040227
AU 2004217977	A1	20040916	AU 2004-217977	20040301
CA 2517361	AA	20040916	CA 2004-2517361	20040301
US 2004229937	A1	20041118	US 2004-789446	20040301
US 2005032798	A1	20050210	US 2004-788405	20040301
US 2005038031	A1	20050217	US 2004-788426	20040301
EP 1599467	A1	20051130	EP 2004-716144	20040301
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004007897	A	20060301	BR 2004-7897	20040301

PRIORITY APPLN. INFO.: US 2003-450323P P 20030228
US 2003-450324P P 20030228
US 2003-450348P P 20030228
WO 2004-US6286 A 20040301
OTHER SOURCE(S): MARPAT 141:277628
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE F(
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:453016 CAPLUS <<LOGINID::20060814>>
DOCUMENT NUMBER: 141:1227
TITLE: Combination cancer therapy with a glutathione S-transferase (GST)-activated anticancer compound and another anticancer therapy
INVENTOR(S): Xu, Hua; Brown, Gail L.; Schow, Steven R.; Keck, James G.
PATENT ASSIGNEE(S): Telik, Inc., USA
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004045593	A2	20040603	WO 2003-US36209	20031114
WO 2004045593	A3	20040812		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				

```
        BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
        ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
        TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    CA 2505377          AA   20040603   CA 2003-2505377        20031114
    AU 2003290805       A1   20040615   AU 2003-290805         20031114
    US 2004138140       A1   20040715   US 2003-714593         20031114
    EP 1562564          A2   20050817   EP 2003-783388         20031114
       R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
        IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
    BR 2003016364       A    20051004   BR 2003-16364          20031114
    CN 1711076          A    20051221   CN 2003-80103404       20031114
    JP 2006508980       T2   20060316   JP 2004-553614         20031114
PRIORITY APPLN. INFO.:                  US 2002-426983P    P  20021115
                                WO 2003-US36209    W  20031114
OTHER SOURCE(S):        MARPAT 141:1227


=> s combinatination
         0 COMBINATINATION
L5       0 COMBINATINATION

=> s combination
     470601 COMBINATION
     110564 COMBINATIONS
L6    557159 COMBINATION
           (COMBINATION OR COMBINATIONS)

=> s l6 and l1
L7       16 L6 AND L1

=> s l7 not py>2002
    4187833 PY>2002
L8        2 L7 NOT PY>2002

=> d ibib 1-2

L8  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:       2001:316848  CAPLUS <<LOGINID::20060814>>
DOCUMENT NUMBER:        135:116763
TITLE:                  The influence of GST-targeted drugs on cell
                        proliferation and stress response
AUTHOR(S):              Tew, Kenneth D.
CORPORATE SOURCE:       Department of Pharmacology, Fox Chase Cancer Center
                        Philadelphia, PA, USA
SOURCE:                 Chemico-Biological Interactions (2001), 133(1-3),
                        295-300
                        CODEN: CBINA8; ISSN: 0009-2797
PUBLISHER:              Elsevier Science Ireland Ltd.
DOCUMENT TYPE:          Journal
LANGUAGE:               English
REFERENCE COUNT:        5    THERE ARE 5 CITED REFERENCES AVAILABLE FO
                        RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8  ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:       2000:466901  CAPLUS <<LOGINID::20060814>>
DOCUMENT NUMBER:        133:171845
TITLE:                  Cellular response to a glutathione S-transferase P1-1
                        activated prodrug
AUTHOR(S):              Rosario, Lilliam A.; O'Brien, Miechelle L.; Henderson,
                        Colin J.; Wolf, C. Roland; Tew, Kenneth D.
CORPORATE SOURCE:       Department of Pharmacology, Fox Chase Cancer Center
                        Philadelphia, PA, USA
SOURCE:                 Molecular Pharmacology (2000), 58(1), 167-174
                        CODEN: MOPMA3; ISSN: 0026-895X
PUBLISHER:              American Society for Pharmacology and Experimental
                        Therapeutics
DOCUMENT TYPE:          Journal
LANGUAGE:               English
REFERENCE COUNT:        28   THERE ARE 28 CITED REFERENCES AVAILABLE
                        RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d ibib abs kwic 1-2
```

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:316848 CAPLUS <<LOGINID::20060814>>
DOCUMENT NUMBER: 135:116763
TITLE: The influence of GST-targeted drugs on cell proliferation and stress response
AUTHOR(S): Tew, Kenneth D.
CORPORATE SOURCE: Department of Pharmacology, Fox Chase Cancer Center Philadelphia, PA, USA
SOURCE: Chemico-Biological Interactions (2001), 133(1-3), 295-300
CODEN: CBINA8; ISSN: 0009-2797
PUBLISHER: Elsevier Science Ireland Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Novel approaches to target GSTP-1 have produced two new anticancer drugs. A GSTP1-1 activated nitrogen mustard prodrug (TER286) is selectively cytotoxic to tumors, which express high levels of the isoenzyme. Cells transfected with GSTP1-1 are more sensitive to the drug and resistant cells down regulate GSTP1-1 expression. A peptidomimetic inhibitor of GSTP1-1 (TER199) which modulates drug resistance when given in ***combination*** with either alkylating agents or natural products also ameliorated drug-induced bone marrow suppressive effects and possessed myeloproliferative activity. This effect is consistent with drug induced dissocn. of GSTP1-1 from JNK with resultant downstream proliferative effects.
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FO RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
AB Novel approaches to target GSTP-1 have produced two new anticancer drugs. A GSTP1-1 activated nitrogen mustard prodrug (TER286) is selectively cytotoxic to tumors, which express high levels of the isoenzyme. Cells transfected with GSTP1-1 are more sensitive to the drug and resistant cells down regulate GSTP1-1 expression. A peptidomimetic inhibitor of GSTP1-1 (TER199) which modulates drug resistance when given in ***combination*** with either alkylating agents or natural products also ameliorated drug-induced bone marrow suppressive effects and possessed myeloproliferative activity. This effect is consistent with drug induced dissocn. of GSTP1-1 from JNK with resultant downstream proliferative effects.
IT 148-82-3, Melphalan 15663-27-1, Cisplatin 25316-40-9, Adriamycin 33069-62-4, Taxol 168682-53-9, TER199 ***439943-59-6*** , TER 286
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(influence of glutathione S-transferase-targeted anticancer drugs on cell proliferation and stress response)

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:466901 CAPLUS <<LOGINID::20060814>>
DOCUMENT NUMBER: 133:171845
TITLE: Cellular response to a glutathione S-transferase P1-1 activated prodrug
AUTHOR(S): Rosario, Lilliam A.; O'Brien, Miechelle L.; Henderson, Colin J.; Wolf, C. Roland; Tew, Kenneth D.
CORPORATE SOURCE: Department of Pharmacology, Fox Chase Cancer Center Philadelphia, PA, USA
SOURCE: Molecular Pharmacology (2000), 58(1), 167-174
CODEN: MOPMA3; ISSN: 0026-895X
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English
AB TER286 [.gamma.-glutamyl-.alpha.-amino-.beta.(2-ethyl-N,N,N',N'-tetrakis(2-chl oroethyl)phosphorodiamidate)-sulfonyl-propionyl-(R)-(-) phenylglycine] is a novel nitrogen mustard prodrug that is preferentially activated by glutathione S-transferase P1-1 (GSTP1-1). A human promyelocytic leukemia /TER286-resistant cell line was selected by chronic, long-term exposure to the prodrug. Although resistance was not readily achieved, eventually a 5-fold resistant clone was isolated. Cross-resistance to melphalan occurred, but not to doxorubicin (Adriamycin), taxol, and .gamma.-glutamyl-S-(benzyl)cysteinyl-R(-)-Ph glycine di-Et ester, a GSTP1-1 inhibitor. The protein and transcript levels and enzymic activity of GSTP1-1 were reduced significantly in the selected resistant line. GST.alpha. levels were unchanged, and GST.mu. was undetectable. Although glutathione levels were elevated in human promyelocytic leukemia/TER286

cells, no changes in the expression of thiol-related genes including .gamma.-glutamylcysteine synthetase, .gamma.-glutamyl transpeptidase, or multidrug resistance protein were found. A 7-fold increase in catalase expression in the resistant cell line indicated an adaptive response to oxidative and electrophilic stress, and this was also reflected in the lower prevalence of drug-induced DNA single-strand breaks in the resistant cells. Mouse embryo fibroblast GSTP1-1-/- cells exhibited 2-fold resistance to TER286 compared with GSTP1-1+/+ cells. NIH3T3 cells transfected with ***combinations*** of .gamma.-GCS and multidrug resistance protein exhibited enhanced resistance to TER286, although the degree of resistance was impaired by co-transfection of GSTP1-1. These results are consistent with responses in the TER286-resistant cells indicative of GSTP1-1-mediated mechanism of activation. In consequence, these data support the rationale that tumors expressing high levels of GSTP1-1 will be more sensitive to the cytotoxic effects of the drug.
REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
AB TER286 [.gamma.-glutamyl-.alpha.-amino-.beta.(2-ethyl-N,N,N',N'-tetrakis(2-chl oroethyl)phosphorodiamidate)-sulfonyl-propionyl-(R)-(-) phenylglycine] is a novel nitrogen mustard prodrug that is preferentially activated by glutathione S-transferase P1-1 (GSTP1-1). A human promyelocytic leukemia /TER286-resistant cell line was selected by chronic, long-term exposure to the prodrug. Although resistance was not readily achieved, eventually a 5-fold resistant clone was isolated. Cross-resistance to melphalan occurred, but not to doxorubicin (Adriamycin), taxol, and .gamma.-glutamyl-S-(benzyl)cysteinyl-R(-)-Ph glycine di-Et ester, a GSTP1-1 inhibitor. The protein and transcript levels and enzymic activity of GSTP1-1 were reduced significantly in the selected resistant line. GST.alpha. levels were unchanged, and GST.mu. was undetectable. Although glutathione levels were elevated in human promyelocytic leukemia/TER286 cells, no changes in the expression of thiol-related genes including .gamma.-glutamylcysteine synthetase, .gamma.-glutamyl transpeptidase, or multidrug resistance protein were found. A 7-fold increase in catalase expression in the resistant cell line indicated an adaptive response to oxidative and electrophilic stress, and this was also reflected in the lower prevalence of drug-induced DNA single-strand breaks in the resistant cells. Mouse embryo fibroblast GSTP1-1-/- cells exhibited 2-fold resistance to TER286 compared with GSTP1-1+/+ cells. NIH3T3 cells transfected with ***combinations*** of .gamma.-GCS and multidrug resistance protein exhibited enhanced resistance to TER286, although the degree of resistance was impaired by co-transfection of GSTP1-1. These results are consistent with responses in the TER286-resistant cells indicative of GSTP1-1-mediated mechanism of activation. In consequence, these data support the rationale that tumors expressing high levels of GSTP1-1 will be more sensitive to the cytotoxic effects of the drug.
IT 148-82-3, Melphalan 23214-92-8, Doxorubicin ***439943-59-6*** , TER 286
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effect of exposure to a glutathione S-transferase P1-1 activated prodrug on antitumor agent resistance of human promyelocytic leukemia cell lines)

=> TER199/cn
TER199 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s TER199/cn
*** REG1stRY INITIATED ***
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L10 0 L9

```
=> s TER 199/cn
   *** REG1stRY INITIATED ***
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L12        17 L11

=> s combined or combination
      460593 COMBINED
      470601 COMBINATION
      110564 COMBINATIONS
      557159 COMBINATION
             (COMBINATION OR COMBINATIONS)
L13     965782 COMBINED OR COMBINATION

=> s l13 and l12
L14         4 L13 AND L12

=> d ibib 1-4

L14  ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:       2003:683236  CAPLUS <<LOGINID::20060814>>
DOCUMENT NUMBER:        140:122233
TITLE:                  Reversal of multiple drug resistance in
                        cholangiocarcinoma by the glutathione
                        S-transferase-.pi.-specific inhibitor
                        O1-hexadecyl-.gamma.-glutamyl-S-benzylcysteinyl-D-
                        phenylglycine Ethylester
AUTHOR(S):              Nakajima, Takaharu; Takayama, Tetsuji; Miyanishi,
                        Koji; Nobuoka, Atsushi; Hayashi, Tsuyoshi; Abe,
                        Tomoyuki; Kato, Junji; Sakon, Kiyoyuki; Naniwa,
                        Yoshimitsu; Tanabe, Hirohumi; Niitsu, Yoshiro
CORPORATE SOURCE:       Fourth Department of Internal Medicine, Sapporo
                        Medical University School of Medicine, Sapporo, Japan
SOURCE:                 Journal of Pharmacology and Experimental Therapeutics
                        (2003), 306(3), 861-869
                        CODEN: JPETAB; ISSN: 0022-3565
PUBLISHER:              American Society for Pharmacology and Experimental
                        Therapeutics
DOCUMENT TYPE:          Journal
LANGUAGE:               English
REFERENCE COUNT:        35    THERE ARE 35 CITED REFERENCES AVAILABLE
                        RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14  ANSWER 2 OF 4  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:       2003:414079  CAPLUS <<LOGINID::20060814>>
DOCUMENT NUMBER:        138:406943
TITLE:                  Pharmaceutical compositions containing glutathione
                        analogs
INVENTOR(S):            Kauvar, Lawrence M.; Lum, Robert T.; Lyttle, Matthew
                        H.; Macsata, Robert W.; Schow, Steven R.; Villar, Hugo
                        O.; Kozlowski, Michael R.
PATENT ASSIGNEE(S):     USA
SOURCE:                 U.S. Pat. Appl. Publ., 16 pp.
                        CODEN: USXXCO
DOCUMENT TYPE:          Patent
LANGUAGE:               English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

    PATENT NO.          KIND  DATE       APPLICATION NO.      DATE
    --------------      ----  --------   -------------------  --------
    US 2003100511       A1    20030529   US 2001-903442       20010710
    US 7029695          B2    20060418
PRIORITY APPLN. INFO.:                   US 2001-903442       20010710
OTHER SOURCE(S):        MARPAT 138:406943
REFERENCE COUNT:        17    THERE ARE 17 CITED REFERENCES AVAILABLE
                        RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

L14 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:364945 CAPLUS <<LOGINID::20060814>>
DOCUMENT NUMBER: 139:207702
TITLE: Resistance to phorbol 12-myristate 13-acetate-induced cell growth arrest in an HL60 cell line chronically exposed to a glutathione S-transferase .pi. inhibitor
AUTHOR(S): Gate, Laurent; Lunk, Alexandra; Tew, Kenneth D.
CORPORATE SOURCE: Department of Pharmacology, Fox Chase Cancer Center Philadelphia, PA, 19111, USA
SOURCE: Biochemical Pharmacology (2003), 65(10), 1611-1622
CODEN: BCPCA6; ISSN: 0006-2952
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:316848 CAPLUS <<LOGINID::20060814>>
DOCUMENT NUMBER: 135:116763
TITLE: The influence of GST-targeted drugs on cell proliferation and stress response
AUTHOR(S): Tew, Kenneth D.
CORPORATE SOURCE: Department of Pharmacology, Fox Chase Cancer Center Philadelphia, PA, USA
SOURCE: Chemico-Biological Interactions (2001), 133(1-3), 295-300
CODEN: CBINA8; ISSN: 0009-2797
PUBLISHER: Elsevier Science Ireland Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FO
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d kwic 2

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AB . . . hematopoiesis, protect hematopoietic cells from damage caused by radiation or chemotherapy, or potentiate the stimulatory action of one or a ***combination*** of cytokines on colony formation by hematopoietic progenitor cells, protect a subject from a destructive effect of a chemotherapeutic agent. . .
IT ***168682-53-9P*** 286942-97-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pharmaceutical compns. contg. glutathione analogs)

=> file pctfull
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 11.31 61.97

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE -0.75 -2.25

FILE 'PCTFULL' ENTERED AT 09:39:36 ON 14 AUG 2006
COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED: 8 AUG 2006 <20060808/UP>
MOST RECENT UPDATE WEEK: 200631 <200631/EW>
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOW AVAILABLE IN THIS FILE.
SEE
http://www.stn-international.de/stndatabases/details/ipc-reform.html >>>

>>> FOR CHANGES IN PCTFULL PLEASE SEE HELP CHANGE

(last updated April 10, 2006) <<<

>>> NEW PRICES IN PCTFULL AS OF 01 JULY 2006. FOR DETAILS,
PLEASE SEE HELP COST <<<

=> s TER () (286 or 199)
64391 TER
9512 TERS
69137 TER
(TER OR TERS)
38923 286
65479 199
L15 15 TER (W) (286 OR 199)

=> s combination or combined
452833 COMBINATION
199923 COMBINATIONS
492208 COMBINATION
(COMBINATION OR COMBINATIONS)
331462 COMBINED
3 COMBINEDS
331463 COMBINED
(COMBINED OR COMBINEDS)
L16 564675 COMBINATION OR COMBINED

=> s l15 and l16
L17 14 L15 AND L16

=> s l17 not py>2001
533324 PY>2001
L18 5 L17 NOT PY>2001

=> d ibib 1-5

L18 ANSWER 1 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1999037802 PCTFULL ED 20020515 <<LOGINID::2006C
TITLE (ENGLISH): METHODS TO IDENTIFY MYELOSTIMULANTS
TITLE (FRENCH): METHODES D'IDENTIFICATION DE MYELOSTIMULANTS
INVENTOR(S): KAUVAR, Lawrence, M.
PATENT ASSIGNEE(S): TELIK, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9937802	A1	19990729

DESIGNATED STATES
W: AU CA GD IN JP AT BE CH CY DE DK ES FI FR GB GR IE IT
LU MC NL PT SE
APPLICATION INFO.: WO 1999-US765 A 19990114
PRIORITY INFO.: US 1998-09/010,390 19980121

L18 ANSWER 2 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1997025342 PCTFULL ED 20020514 <<LOGINID::2006C
TITLE (ENGLISH): TETHERED PRODRUGS BY VIRTUE OF COVALENT LINKAC
ANALOGS OF GLUTATHIONE
TITLE (FRENCH): PRECURSEURS DE MEDICAMENTS LIES PAR UNE LIAISOI
COVALENTE A L'AIDE D'ANALOGUES DE GLUTATHIONE
INVENTOR(S): LYTTLE, Matthew, H.;
KAUVAR, Lawrence, M.
PATENT ASSIGNEE(S): TERRAPIN TECHNOLOGIES, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9725342	A1	19970717

DESIGNATED STATES
W: AU CA JP AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL
PT SE
APPLICATION INFO.: WO 1996-US20042 A 19961220
PRIORITY INFO.: US 1996-8/582,966 19960104

L18 ANSWER 3 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN

ACCESSION NUMBER: 1996040205 PCTFULL ED 20020514 <<LOGINID::2006C
TITLE (ENGLISH): METABOLIC EFFECTS OF CERTAIN GLUTATHIONE ANALO
TITLE (FRENCH): EFFETS METABOLIQUES DE CERTAINS ANALOGUES DE GLUTATHIONE
INVENTOR(S): KAUVAR, Lawrence, M.;
LYTTLE, Matthew, H.;
MORGAN, Amy, S.;
BORCH, Richard, F.
PATENT ASSIGNEE(S): TERRAPIN TECHNOLOGIES, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9640205	A1	19961219

DESIGNATED STATES
W: AL AM AU BB BG BR CA CN CZ EE GE HU IL IS JP KG KP KR LK LR LT LV MD MG MK MN MX NO NZ PL RO SG SI SK TR TT UA UZ VN KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
APPLICATION INFO.: WO 1996-US9057 A 19960605
PRIORITY INFO.: US 1995-8/482,645 19950607
US 1996-8/636,516 19960419

L18 ANSWER 4 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1995009866 PCTFULL ED 20020514 <<LOGINID::2006C
TITLE (ENGLISH): GLUTATHIONE S-TRANSFERASE-ACTIVATED COMPOUND
TITLE (FRENCH): COMPOSES ACTIVES PAR LA GLUTATHIONE S-TRANSFEI
INVENTOR(S): KAUVAR, Lawrence, M.;
LYTTLE, Matthew, H.;
SATYAM, Apparao
PATENT ASSIGNEE(S): TERRAPIN TECHNOLOGIES, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9509866	A1	19950413

DESIGNATED STATES
W: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.: WO 1994-US11109 A 19940930
PRIORITY INFO.: US 1993-8/130,736 19931001
US 1994-8/309,005 19940919

L18 ANSWER 5 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1995009865 PCTFULL ED 20020514 <<LOGINID::2006C
TITLE (ENGLISH): GLUTATHIONE S-TRANSFERASE-ACTIVATED COMPOUND
TITLE (FRENCH): COMPOSES ACTIVES PAR LA GLUTATHIONE S-TRANSFEI
INVENTOR(S): KAUVAR, Lawrence, M.;
LYTTLE, Matthew, H.;
SATYAM, Apparao
PATENT ASSIGNEE(S): TERRAPIN TECHNOLOGIES, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9509865	A1	19950413

DESIGNATED STATES
W: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.: WO 1994-US10796 A 19940923
PRIORITY INFO.: US 1993-8/130,736 19931001
US 1994-8/130,736 19940919

=> d kwic 2-5

L18 ANSWER 2 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD However, TER 117 does not. A prodrug constructed from TER 117 as described in the above-referenced PCT

application, ***TER*** ***286*** , has the desired isoenzyme specificity for cells having GST complements high in the P1-1 isoform; however, this form of the prodrug would. . .

. . .

or acid at a temperature of from about OOC to about 1000C, preferably at room temperELture either in water alone or in ***combination*** with an inert water-miscible organic solvent such as methanol, ethanol or dioxane.

. . .

in the PCT application, TER 231 is especially susceptible to cleavage by GST Mla-la; TER 303 is especially susceptible to cleavage by Al-1; ***TER*** ***286*** is particularly susceptible to cleavage by P1-1 and Al-1, while TER 296 is selectively cleaved by P1 Thus, in treating a tumor having elevated levels of P1 use of a compound of formula (1) having the tripeptide contained in TER 296 or ***TER*** ***286*** would be preferred. The relevant isoenzyme, GST P1-1 is elevated in more than 75% of human tumor specimens from breast, lung, liver. . .

L18 ANSWER 3 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD . . . toxic effect of TER199 in contrast to its unesterified form on HT4-1 cells, Figure 2 is a graph showing the effect of various ***combinations*** of chlorambucil either alone or in ***combination*** with ethacrynic acid or TER199.

. . .

in tumor cells. Third, the compounds of formula (1) directly potentiate the effect of chemotherapeutic agents in the destruction of tumor cells. This ***combination*** of qualities makes the compounds of the invention useful both as hematopoiesis potentiating agents directly and to ameliorate the negative effects of chemotherapeutic. . .

. . .

CMB, reducing the concentration CMB needed for 50% cell killing by a DMF of 1,08, In contrast the diethyl ester of 7E-C(Bz)-qG (***TER*** ***199***) at only 12.5 pM enhanced CMB cytotoxicity by a factor.of 1 Preferential expression of GST isoenzyme P1-1 has been reported in a. . .

. . .

5 when TER199 was administered along with the melphalan, the tumor volume mean was approximately 55% of control. For group 4 administered a ***combination*** of melphalan and ethacrynic acid, the volumes were approximately 35% of control. Thus, both ethacrynic acid and TER199 potentiate the effects of. . .

. . .

GM-CSFI G-CSFI M-CSFI Flt3/Flk-2 and Steel factor (stem cell factor/c-kit ligand). Of particular interest was the finding that TER199 enhances colony formation stimulated by ***combinations*** of cytokines. Additionally, the enhancing effect is more pronounced in human than in murine bone marrow, These results suggest that TER199 has. . .

. . .

(60)* 65±4 (44)* 67±5 (49)* 50ng)
'Statistically significant
Table 5: Influence of TER199 on colony formation by normal human bone marrow GM-progenitor cells stimulated by ***combinations*** of cytokines.

L18 ANSWER 4 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD Properties and Distribution of GST Isoenzymes
The various GST isoenzymes are dimeric proteins formed

by binary ***combinations*** of monomers encoded by at least fifteen known genes in four gene families, resulting in the theoretical possibility of several dozen different. . .

. . .

availability of a substantial family of isoenzymes which is unevenly distributed as to its members with respect to normal and tumor tissue, ***combined*** with differences between the family members in substrate specificity and inhibitor sensitivity, makes this family an important target for designing therapies for conditions. . .

Figures 3a and 3b are graphs showing the decomposition of ***TER*** ***286*** and TER 322 by various GSTs.

Figure 5 shows the effect of ***TER*** ***286*** on growth of tumors in mice.

Figure 6 shows the effect of 100-200 mg/kg ***TER*** ***286*** on the GM-CFU in bone marrow of mice.

Figure 7 shows the dose-dependence of bone marrow GM-CFU for administration of ***TER*** ***286*** .

Modes of Carrying Out the Invention

The compounds of Formula (1) are prodrugs which can be used selectively to target tissues having. . . specificity to the prodrug provided. As shown below, the prodrugs prepared for illustration, TER 230, as a model compound, and TER 231, ***TER*** ***286*** , TER 296 and TER 303 as effective prodrugs, are differentially activated by GST enzymes of the A, 7 and a classes. These. . .

T-Glutamyl-a-Amino-o-((2-ethyl-N,N,N,N-tetra(2'-chloro)ethylphosphoramidate)sulfonyl)propionylglycine, (TER 231);
is
T-Glutamyl-a-Amino-o-((2-ethyl-N,N,N,N-tetra(21-chloro)ethylphosphoramidate)sulfonyl)propionyl-(R)-(-)-phenylglycine (***TER*** ***286***);
T-Glutamyl-a-Amino-fl-((2-ethyl-N,N,N,N-tetra(21-chloro)ethylphosphoramidate)sulfonyl)propionyl-phenylalanine (TER 303);
7-Glutamyl-a-amino-O-(i-phenyl, 2-ethyl-N,N,N,N-tetra(21-chloroethyl)phosphoramidate)sulfonyl)propionyl glycine (TER 296);
T-Glutamyl-a-amino-fl-(i-phenyl, 2-ethyl-N,N,N,N-tetra(21-chloroethyl)phosphoramidate)sulfonyl)propionyl (R)-(-)-phenylglycine (TER 297);
T-Glutamyl-u-amino-fl(2-ethyl, N,N-bis(2'-chloroethyl)carbamoyl)sulfonyl)propionyl glycine (TER 322) and its diethyl ester (TER 325); and
T-Glutamyl-u-amino-fl-((2-ethyl-(4-benzyloxy(N,.N,N',N' tetrakis(2-chloroethyl)phosphorodiamidate)) carbamido)sulfonyl)propionyl glycine.

. . .

base or acid at a temperature of from about OOC to about 1000C, preferably at room temperature either in water alone or in ***combination*** with an inert water-miscible organic solvent such as methanol, ethanol or dioxane.

. . .

the compounds exemplified below, TER 231 is especially susceptible to cleavage by GST Mla-la; TER 303 is especially susceptible to cleavage by Al-1; ***TER*** ***286*** is particularly susceptible to cleavage by P1-1 and Al-1, while TER 296 is selectively cleaved by P1 Thus, in treating a tumor. . . tumor, they appear to stimulate GM progenitors in bone marrow. There is relatively little organ toxicity and no evidence of leukocytosis. For ***TER*** ***286*** , the relevant isoenzyme, GST P1-1 is elevated in more than

75'i of human tumor specimens from breast, lung, liver and colon.

. . .

synthesis of TER 296 or TER
297, a-amino-fl-sulfhydryl phenylpropionic acid is substituted
for the cysteine residue in the analog. For the synthesis of
TER ***286*** , phenylglycine is substituted for glycine in
the
tripeptide as AAc. For synthesis of TER 303, phenyl alanine is
substituted for glycine as. . .

. . .

a sep. funnel,
and separated. The lower organic layer was saved, and the
aqueous layer was extracted with 100 ml of CH2CL2.The ***combined***
organic phases were washed with 500 ml saturated brine and dried
over Na2SO4. The solution was filtered and reduced to an oil
under. . .

. . .

to separate. The lower organic layer was removed and
sav ed, and the upper layer was extracted with 100 ml CH2Cl2. The
combined CH2C'21ayers were washed six times with 100 ml
portions
- 25
of saturated NaC11 and dried over Na2SO4- The solution was
filtered and. . .

. . .

9:1. The reaction was
quenched with dropwise addition of 100 ml water, and extracted
twice with 250 ml portions of EtOAc. The ***combined*** organic
extracts were washed twice with 100 ml portions of brine and
dried over Na2SO4. This was filtered and evaporated to 8.3. . .

. . .

stirred overnight. The mixture was poured into
35 ml of water and extracted with two 50 ml portions of toluene,
and the ***combined*** organic phases were dried over Na2SO4 and
concentrated to a viscous oil. TLC (9:1 EtOAc:MeOH) showed one
spot, rf 0 UV active.. . .

T-Glutamyl-u-Amino-o-((2-ethyl,-N,N,N,N-tetra(21-
chloro). ethylphosphoramidate)sulfonyl)propionyl-(R)-(-)-
phenylglycine (***TER*** ***286***);
T-Glutamyl-u-Amino-o-((2-ethyl-N,N,N,N-tetra(2'-
chloro)ethylphosphoramidate)sulfonyl)propionyl-phenylalanine
(TER 303);
T-Glutamyl-u-Amino-O-(1-phenyl, (2-ethyl-N,N,N,N-
tetra(2-chloro)ethylphosphoramidate)sulfonyl) propionyl glycine
(TER 296);
T-Glutamyl-u-Amino (1-phenyl, (2-ethyl-N,N,N,N-
tetra(21-chloro)ethylphosphoramidate)sulfonyl) propionyl (R)-(-
)-phenylglycine (TER 297).

Further details with respect to ***TER*** ***286*** are as
follows.

TER ***286*** was similarly tested with the results shown
in
Figure 3a. Both PI-I and AI-I accelerate the cleavage of ***TER***
286 roughly six times faster than background; there is
negligible acceleration of cleavage with Mla-la.

. . .

prodrug
selected, specificity can be obtained for any of the three human
GSTs tested. Thus, TER 29G is selectively cleaved by Pi-1; ***TER***
286 is selectively cleaved by PI-1 and AI-1; TER 303 is
selectively cleaved by AI-1; and TER 231 by Mla-la.

. . .

when
MCF-7 tumor cells transfected by P1-1 were compared to cells
transfected only with the control vector. As shown in Figure
4a, when ***TER*** ***286*** is employed, cells containing high
P1-1 enzyme
levels are sensitized 4-fold to the prodrug compared to
controls; Figure 4b shows a 2-fold. . .

. . .

were obtained for MCF-7 cells which

are sensitive to CTX as compared to CTX-resistant forms. The CTX-resistant cells were more sensitive to ***TER*** ***286*** by a factor
of 1.8 as compared to cells sensitive to CTX in a standard clonogenic assay.

In Figure 5, the squares represent controls; circles represent 300 mg/kg of ***TER*** ***286*** ; triangles represent 400 mg/kg of the same
drug. The points shown are the mean + SEM of 5-7 mice per group.

Examiple 6
Effect of Prodrug on Bone Marrow
In the assay, B6D2F1 mice were treated with various doses of ***TER*** ***286*** intraperitoneally either as a single injection
or as five daily injections. Femoral bone marrows were harvested 24 hours later and assayed for. . . results are shown in Figure 6. Increases up to 1800i of
controls for GM-CFU were obtained with administration of 100-200 mg/kg of ***TER*** ***286*** ; the values shown are the mean plus SD of 2-3
experiments.

Further, as shown in Figure 7, the optimum dosage range appears to be in this region of 100-200 mg/kg for ***TER*** ***286*** .

L18 ANSWER 5 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD Properties and Distribution of GST Isoenzymes
The various GST isoenzymes are dimeric proteins formed by binary ***combinations*** of monomers encoded by at least fifteen known genes in four gene families, resulting in the theoretical possibility of several dozen different. . .
. . .
availability of a substantial family of isoenzymes which is unevenly distributed as to its members with respect to normal and tumor tissue, ***combined*** with differences between the family members in substrate specificity and inhibitor sensitivity, makes this family an important target for designing therapies for conditions. . .
. . .
2 is a graph showing the decomposition of TER 231 by various GSTs,
Figure 3 is a graph showing the decomposition of ***TER*** ***286*** by various GSTs.
. . .
for various chemotherapeutic agents with respect to cells having high or low levels of GST P1
Figure 5 shows the effect of ***TER*** ***286*** on growth of tumors in mice.

Figure 6 shows the effect of 100-200 mg/kg ***TER*** ***286*** on
the GM-CFU in bone marrow of mice.

Figure 7 shows the dose-dependence of bone marrow GM-CFU for administration of ***TER*** ***286*** .

Modes of Carrying Out the Inventio
The compounds of Formula (1) are prodrugs which can be used selectively to target tissues having. . . specificity to the prodrug
provided. As shown below, the prodrugs prepared for illustration, TER 230, as a model compound, and TER 231, ***TER*** ***286*** , TER 296 and TER 303 as effective prodrugs, are differentially activated by GST enzymes of the A, w and a classes. These. . .

T-Glutamyl-a-Amino-fl-((2-ethyl-N,N,N-tetra(21-chloro)ethylphosphoramidate)sulfonyl)propionylglycine, (TER 231)1

7-Glutamyl-a-Amino-O-((2-ethyl-N,N,N,N-tetra(21-
chloro)ethylphosphoramidate)sulfonyl)propionyl-(R)-(-)-
phenylglycine (***TER*** ***286***);
- 13 -
oy-Glutamyl-oi-Amino-O-((2-ethyl-N,N,N,N-tetra(21-
chloro)ethylphosphoramidate)sulfonyl)propionyl-phenylalanine
(TER 303);
T-Glutamyl-a-Amino-fl-(l-phenyl, 2-ethyl-N,N,N,N-
tetra(21-chloro)ethylphosphoramidate)sulfonyl)propionyl glycine
(TER 296);
7-Glutamyl-u-Amino-fl-(1-phenyl, 2-ethyl-N,N,N,N-
tetra(21-chloro)ethylphosphoramidate)sulfonyl)propionyl (R)-(-)-
phenylglycine (TER 297).

. . .

base or
acid at a temperature of from about OOC to about 1000C,
preferably at room temperature either in water alone or in
combination with an inert water-miscible organic solvent such
as
methanol, ethanol or dioxane.

. . .

exemplified below, TER 231 is especially susceptible
5 to cleavage by GST Mla-la; TER 303 is especially susceptible to
cleavage by Al-1; ***TER*** ***286*** is particularly
susceptible to
cleavage by P1-1 and Al-1, while TER 296 is selectively cleaved
by PI Thus, in treating a tumor. . . tumor, they appear to
stimulate GM progenitors in bone marrow, There is relatively
little organ toxicity and no evidence of leukocytosis, For ***TER***
286 , the relevant isoenzyme, GST PI-1 is elevated in more than
75% of human tumor specimens from breast, lung, liver and colon.

. . .

for synthesis of TER 296 or TER
297, a-amino-o-sulfhydryl-o-phenylpropionic acid is substituted
for the cysteine residue in the analog. For the synthesis of
TER ***286*** , phenylglycine is substituted for glycine in
the
tripeptide as AAC. For synthesis of TER 303, phenyl alanine is
substituted for glycine as. . .

. . .

sep. funnel,
and separated. The lower organic layer was saved, and the
aqueous layer was extracted with 100 ml of CH2CL2. The ***combined***
organic phases were washed with 500 ml saturated brine and dried
over Na2SO4. The solution was filtered and reduced to an oil
under. . .

. . .

to separate. The lower organic layer was removed and
35 saved, and the upper layer was extracted with 100 ml CH2C12. The
combined CH2C12 layers were washed six times with 100 ml
portions
- 23
of saturated NaC1, and dried over Na2SO4- The solution was
filtered. . .

. . .

9:1. The reaction was
quenched with dropwise addition of 100 ml water, and extracted
twice with 250 ml portions of EtOAc. The ***combined*** organic
extracts were washed twice with 100 ml portions of brine and
dried over Na2SO4. This was filtered and evaporated to 8.3. . .

. . .

stirred overnight. The mixture was poured into
35 ml of water and extracted with two 50 ml portions of toluene,
and the ***combined*** organic phases were dried over Na2SO4 and
concentrated to a viscous oil. TLC (9:1 EtOAc:MeOH) showed one
spot, rf 0,7, UV active.. . .

7-Glutamyl-u-Amino-g-((2-ethyl-N,N,N,N-tetra(21-
chloro) ethylphosphoramidate)sulfonyl)propionyl-(R)-(-)-
phenylglycine (***TER*** ***286***);
7-Glutamyl-a-Amino-fl-((2-ethyl-N,N,N,N-tetra(21-
chloro)ethylphosphoramidate)sulfonyl)propionyl-phenylalanine
(TER 303);
7-Glutamyl-a-Amino (1-phenyl, (2-ethyl-N,N,N,N-

tetra(21-chloro)ethylphosphoramidate)sulfonyl) propionyl glycine (TER 296);
7-Glutamyl-a-Amino-fl-(l-phenyl, (2-ethyl-N,N,N,N-tetra(21-chloro)ethylphosphoramidate)sulfonyl) propionyl (R)-(-)-phenylglycine (TER 297).

Further details with respect to ***TER*** ***286*** may be found in Lyttle, M.H. et al. J Med Chem (1994) 37:1501-1507; Lyttle, M. et al, J Med Chem (1994) 34:189. . .

TER ***286*** was similarly tested with the results shown in
Figure 3. Both PI-1 and AI-I accelerate the cleavage of ***TER*** ***286*** roughly six times faster than background; there is negligible acceleration of cleavage with Mla-la.

. . .
when
MCF-7 tumor cells transfected by PI-1 were compared to cells transfected only with the control vector. As shown in Figure 4a, when ***TER*** ***286*** is employed, cells containing high P1-1 enzyme
levels are sensitized 4-fLold to the prodrug compared to controls; Figure 4b shows a 2-fold. . .

. . .
obtained for MCF-7 cells which
are sensitive to CTX as compared to CTX-resistant forms. The 25 CTX-resistant cells were more sensitive to ***TER*** ***286*** by a factor
of 1,8 as compared to cells sensitive to CTX in a standard clonogenic assay.

- 33 -
In Figure 5, the squares represent controls; circles represent 300 mg/kg of- ***TER*** ***286*** ; triangles represent 400 mg/kg of the same
drug. The points shown are the mean ± SEM of 5-7 mice per group.

Example 6
Effect of Prodrug on Bone Marrow
In the assay, B6D2F. mice were treated with various doses of ***TER*** ***286*** intraperitoneally either as a single injection
or as five daily injections. Femoral bone marrows were harvested 24 hours later and assayed for. . . results are shown in Figure 6, Increases up to 18016 of
controls for GM-CPU were obtained with administration of 100-200 mg/kg of ***TER*** ***286*** ; the values shown are the mean plus SD of 2-3
experiments.

Further, as shown in Figure 7, the optimum dosage range appears to be in this region of 100-200 mg/kg for ***TER*** ***286*** .

```
=> s cancer? or tumor? or neoplas?
      80405 CANCER?
      67062 TUMOR?
      23301 NEOPLAS?
L19    100034 CANCER? OR TUMOR? OR NEOPLAS?

=> s l19/clm
      23115 CANCER?/CLM
      15601 TUMOR?/CLM
       3791 NEOPLAS?/CLM
L20    32848 (CANCER?/CLM OR TUMOR?/CLM OR NEOPLAS?/CLM)

=> s l20 and l18
L21        2 L20 AND L18

=> d ibib 1-2
```

```
L21   ANSWER 1 OF 2    PCTFULL  COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER:      1999037802 PCTFULL  ED 20020515 <<LOGINID::2006C
TITLE (ENGLISH):       METHODS TO IDENTIFY MYELOSTIMULANTS
TITLE (FRENCH):        METHODES D'IDENTIFICATION DE MYELOSTIMULANTS
INVENTOR(S):           KAUVAR, Lawrence, M.
PATENT ASSIGNEE(S):    TELIK, INC.
LANGUAGE OF PUBL.:     English
DOCUMENT TYPE:         Patent
PATENT INFORMATION:
                       NUMBER          KIND    DATE
                       --------------------------------
                       WO 9937802      A1 19990729
DESIGNATED STATES
    W:                  AU CA GD IN JP AT BE CH CY DE DK ES FI FR GB GR IE IT
                       LU MC NL PT SE
APPLICATION INFO.:     WO 1999-US765      A  19990114
PRIORITY INFO.:        US 1998-09/010,390     19980121

L21   ANSWER 2 OF 2    PCTFULL  COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER:      1995009865 PCTFULL  ED 20020514 <<LOGINID::2006C
TITLE (ENGLISH):       GLUTATHIONE S-TRANSFERASE-ACTIVATED COMPOUND
TITLE (FRENCH):        COMPOSES ACTIVES PAR LA GLUTATHIONE S-TRANSFEF
INVENTOR(S):           KAUVAR, Lawrence, M.;
                       LYTTLE, Matthew, H.;
                       SATYAM, Apparao
PATENT ASSIGNEE(S):    TERRAPIN TECHNOLOGIES, INC.
LANGUAGE OF PUBL.:     English
DOCUMENT TYPE:         Patent
PATENT INFORMATION:
                       NUMBER          KIND    DATE
                       --------------------------------
                       WO 9509865      A1 19950413
DESIGNATED STATES
    W:                  AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT
                       SE
APPLICATION INFO.:     WO 1994-US10796     A  19940923
PRIORITY INFO.:        US 1993-8/130,736      19931001
                       US 1994-8/130,736      19940919


=> s l19 and l8
'RN' IS NOT A VALID FIELD CODE
      452833 COMBINATION
      199923 COMBINATIONS
      492208 COMBINATION
             (COMBINATION OR COMBINATIONS)
           0 439943-59-6/RN
      429338 PY>2002
L22         0 L19 AND L8

=> s l19 and l18
L23         5 L19 AND L18

=> d kwic 3

L23   ANSWER 3 OF 5    PCTFULL  COPYRIGHT 2006 Univentio on STN

DETD . . . effects
      can be neutropenia, thrombocytopenia and immune
      suppression generally. These side effects are not only
      unpleasant, but they also restrict the efficacy of  ***cancer***
      therapy and place the subject at serious risk of
      infection and uncontrolled bleeding.

      Disclosure of the Invention
      The invention provides compounds which are useful in
      modulating hematopoiesis generally and as aids to
      chemotherapeutic treatment of  ***tumors***  by virtue of their
      ability to exert a protective effect on the hematopoietic
      system with respect to toxic agents which are otherwise
      useful. . .
. . .
      cell populations in the
      course of bone marrow transplantation. The invention is
```

further directed to the use of compounds of the invention as ***tumor*** -specific chemo- or radiosensitizers, thus potentiating the effect of treatment, and as generalized chemoprotectants,
The invention also includes pharmaceutical compositions containing the compounds of the. . .

Brief Description of the Drawings
Figure Ia shows the effect of TER199 on the survival of ***tumor*** cells treated with various concentrations of chlorambucil.

. . .
toxic effect of TER199 in contrast to its unesterified form on HT4-1 cells,
Figure 2 is a graph showing the effect of various ***combinations*** of chlorambucil either alone or in ***combination*** with ethacrynic acid or TER199.

. . .
chemotherapeutic agents, Second, they usually inhibit at least one class of the GST isoenzymes, including the n subclass, which is particularly prevalent in ***tumor*** cells. Third, the compounds of formula (1) directly potentiate the effect of chemotherapeutic agents in the destruction of ***tumor*** cells. This ***combination*** of qualities makes the compounds of the invention useful both as hematopoiesis potentiating agents directly and to ameliorate the negative effects of chemotherapeutic. . .

. . .
Example 1
Use of the Compounds of the Invention in Potentiation of Cytotoxic Agents in Human Cells
This example describes: 1) potentiation in human ***tumor*** cells of a cytotoxic agent currently used in ***cancer*** chemotherapy by GST inhibitors, including compounds of the present invention, as well as 2) enhanced intracellular efficacy of esterified forms of these compounds,
HT-29 (human colon adenocarcinoma) cells were obtained from Dr, Roberto Ceriani (***Cancer*** Research Fund of Contra Costa County, Walnut Creek, CA) and were used it log phase of growth unless otherwise specified.

The results in Tables 1-3 show that several GSH analogs found to be inhibitors of GSH also potentiate killing of human ***tumor*** cells in culture by CMB which is a substrate for various GSTs. Results of potentiation tests with several GST inhibitors in HT29. . .

. . .
CMB, reducing the concentration CMB needed for 50% cell killing by a DMF of 1,08, In contrast the diethyl ester of 7E-C(Bz)-qG (***TER*** ***199***) at only 12.5 pM enhanced CMB cytotoxicity by a factor.of 1
Preferential expression of GST isoenzyme P1-1 has been reported in a range of human ***tumors*** . In the present study the efficacy of CMB potentiation of the several GST inhibitors tested correlated directly with their
- 18 -
potencies as. . .

Example 2
Potentiation of Melphalan Toxicity in vivo
Male scid mice were subcutaneously implanted with HT4-1 ***tumors*** from donor mice. HT4-1 is a subclone of HT-29, a human colon ***cancer*** . When ***tumors*** reached approximately 100 MM3, the mice were randomized into six treatment groups and treated for seven days as follows.

The mice were monitored for weight changes and ***tumor*** volumes were determined by measurement with calipers.

The ***tumor*** growth was monitored until the average ***tumor***

size reached 1500 MM3 for all groups except melphalan with ethacrynic acid. This group failed to reach this volume even after 72 days.

The results were computed in terms of the ***tumor*** volume in the drug treated mice as a percentage of control ***tumor*** volume (i.e., in the group administered vehicle alone). In group 11 administered melphalan alone, the ***tumors*** were approximately 75% of the volume of controls. In group 5 when TER199 was administered along with the melphalan, the ***tumor*** volume mean was approximately 55% of control. For group 4 administered a ***combination*** of melphalan and ethacrynic acid, the volumes were approximately 35% of control. Thus, both ethacrynic acid and TER199 potentiate the effects of melphalan, (The volume measurements were taken at the time control ***tumors*** reached 1500 nun3

Example 3

Metabolic Effects of the Invention Compounds

The metabolic effects related to toxicity of the compounds of the invention on. . .

. . .

PG intraperitoneally. Femoral bone marrows were harvested 24 hours later and assayed for GM-CFU by the method of East, C.J. et. al. ***Cancer*** Chemother Pharmacol (1992) 31:123 An increase in the number of colonies in a dose-dependent manner up to a dosage of 90 mg/kg. . .

. . .

GM-CSFI G-CSFI M-CSFI Flt3/Flk-2 and Steel factor (stem cell factor/c-kit ligand). Of particular interest was the finding that TER199 enhances colony formation stimulated by ***combinations*** of cytokines. Additionally, the enhancing effect is more pronounced in human than in murine bone marrow, These results suggest that TER199 has. . .

. . .

(60)* 65±4 (44)* 67±5 (49)* 50ng)

'Statistically significant

Table 5: Influence of TER199 on colony formation by normal human bone marrow GM-progenitor cells stimulated by ***combinations*** of cytokines.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	SESSION	TOTAL
FULL ESTIMATED COST		20.52	82.49

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	SESSION	TOTAL
CA SUBSCRIBER PRICE		0.00	-2.25

STN INTERNATIONAL LOGOFF AT 09:45:04 ON 14 AUG 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 4 APR 04 STN AnaVist $500 visualization usage credit offered
NEWS 5 MAY 10 CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 6 MAY 11 KOREAPAT updates resume
NEWS 7 MAY 19 Derwent World Patents Index to be reloaded and enhanced
NEWS 8 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS 9 MAY 30 The F-Term thesaurus is now available in CA/CAplus
NEWS 10 JUN 02 The first reclassification of IPC codes now complete in INPADOC
NEWS 11 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS 12 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 13 JUl 11 CHEMSAFE reloaded and enhanced
NEWS 14 JUl 14 FSTA enhanced with Japanese patents
NEWS 15 JUl 19 Coverage of Research Disclosure reinstated in DWPI
NEWS 16 AUG 09 INSPEC enhanced with 1898-1968 archive

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:55:27 ON 14 AUG 2006

=> file reg
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 09:55:37 ON 14 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 AUG 2006 HIGHEST RN 900864-99-5
DICTIONARY FILE UPDATES: 11 AUG 2006 HIGHEST RN 900864-99-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

```
=> E "TER 199"/CN 25
E1          1    TER 17210/CN
E2          1    TER 183/CN
E3          1 --> TER 199/CN
E4          1    TER 200/CN
E5          1    TER 206/CN
E6          1    TER 211/CN
E7          1    TER 230/CN
E8          1    TER 231/CN
E9          1    TER 286/CN
E10         1    TER 317/CN
E11         1    TER 322/CN
E12         1    TER 324/CN
E13         1    TER 338/CN
E14         1    TER 3938/CN
E15         1    TER 838/CN
E16         1    TER 838, POLYMER WITH TEDIMON 316/CN
E17         1    TER 930180/CN
E18         1    TER BINDING PROTEIN (PLASMID RTS1 GENE ORF91)/CN
E19         1    TER HELL 5603/CN
E20         1    TER HELL 6805/CN
E21         5    TER(5,6)FULLERENE-C50-D5H(6)/CN
E22         3    TER(5,6)FULLERENE-C50-D5H(6), DOCOSAHYDRO-/CN
E23         2    TER(5,6)FULLERENE-C50-D5H(6), OCTADECAHYDRO-/CN
E24         1    TER-1H-INDOLE, 2,2',2'',3,3',3''-HEXAPHENYL-/CN
E25         1    TER-9H-CARBAZOLE/CN

=> S E3
L1          1 "TER 199"/CN

=> DIS L1 1 SQIDE
THE ESTIMATED COST FOR THIS REQUEST IS 6.36 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2006 ACS on STN
RN  168682-53-9  REGISTRY
CN  Glycine, L-.gamma.-glutamyl-S-(phenylmethyl)-L-cysteinyl-2-phenyl-,
    diethyl ester, (2R)- (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN  Glycine, N-[N-L-.gamma.-glutamyl-S-(phenylmethyl)-L-cysteinyl]-D-2-phenyl-
    , diethyl ester
OTHER NAMES:
CN    ***Ter 199***
CN  Terrapin 199
CN  TLK 199
FS  STEREOSEARCH
MF  C27 H35 N3 O6 S
CI  COM
SR  CA
LC  STN Files:  ADISINSIGHT, BIOSIS, CA, CAPLUS, DDFU, DRUGU, IMSDRUGNE
    IMSPATENTS, IMSRESEARCH, PHAR, PROUSDDR, TOXCENTER, USPAT2, U
DT.CA  CAplus document type:  Journal; Patent
RL.P  Roles from patents:  BIOL (Biological study); PREP (Preparation); USES
    (Uses)
RL.NP  Roles from non-patents:  BIOL (Biological study); USES (Uses)

Absolute stereochemistry.

/ Structure 2 in file .gra /


**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

          17 REFERENCES IN FILE CA (1907 TO DATE)
          17 REFERENCES IN FILE CAPLUS (1907 TO DATE)
```

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		7.10	7.31

STN INTERNATIONAL LOGOFF AT 09:56:27 ON 14 AUG 2006